Update on PSMA Theranostics PETAUC & FDG in RPT Eligibility

Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI Professor of Radiology, Urology & Biomedical Engineering Past President, American College of Nuclear Medicine Past President, Society of Nuclear Medicine and Molecular Imaging



USC Norris Comprehensive Cancer Center Part of the Keck School of Medicine of USC







Financial Disclosures:

- Investigator ullet
 - NIH \bullet
 - Gnana Ming Hsieh Institute \bullet
- **Advisory Board**
 - Radiomedix \bullet
 - Pharmalogic \bullet
- Consultant \bullet
 - **Blue Earth Diagnostics** \bullet

RMTH


- Bayer \bullet
- Speaker's Bureau \bullet
 - Lantheus \bullet





PSMA PET Appropriate Use Criteria

PSMA PET



Jadvar,....,Hope. J Nucl Med **January 2022 APPROPRIATE USE CRITERIA**

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

Hossein Jadvar¹, Jeremie Calais², Stefano Fanti³, Felix Feng⁴, Kirsten L. Greene⁵, James L. Gulley⁶, Michael Hofman² Bridget F. Koontz⁸, Daniel W. Lin⁹, Michael J. Morris¹⁰, Steve P. Rowe¹¹, Trevor J. Royce¹², Simpa Salami¹³, Bital Savir-Baruch¹⁴, Sandy Srinivas¹⁵, and Thomas A. Hope¹⁶

¹Department of Radiology, University of Southern California, Los Angeles, California; ²Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California; ³University of Bologna, Bologna, Italy, ⁴Department of Radiation Oncology, University of California, San Francisco, California; Department of Urology, University of Virginia, Charlottesville, Virginia; ⁶National Institutes of Health, Bethesda, Maryland; ⁷Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria Australia; ⁸Department of Radiation Oncology, Duke University, Durham, North Carolina; ⁹Department of Urology, University of Washington, Seattle, Washington; ¹⁰Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; ¹¹Department of Radiological Sciences, Johns Hopkins University, Baltimore, Maryland; ¹²Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina; ¹³Department of Urology, University of Michigan, Ann Arbor, Michigan;¹⁴Department of Radiology, Loyola University, Maywood, Illinois;¹⁵Department of Medicine (Oncology), Stanford University, California; and ¹⁶Department of Radiology and Biomedical Imaging, University of California, San Francisco, California

SNMMI, ACNM, ASCO, AUA, EANM, ACP, ANZSNM

Updates to Appropriate Use Criteria for PSMA PET

Thomas A. Hope, MD. University of California, San Francisco, CA; and Hossein Jadvar, MD, PhD, MPH, MBA, University of Southern California, Los Angeles, CA

(AUC) for Prostate-Specific Membrane Antigen (PSMA) PET document has been updated (1). This is able disease with uptake less than that in the liver (2). Eligibildue to the recent U.S. Food and Drug Administration (FDA) approval of ¹⁷⁷Lu-PSMA-617 (Pluvicto, ¹⁷⁷Lu-vipivotide tetraxetan; Novartis [Basel, Switzerland]/Advanced Accelerator Applications USA, Inc. [Millburn, NJ]) radiopharmaceutical therapy (RPT). Previously the AUC had scored the indication for a posttreatment prostate-specific antigen (PSA) rise in the metastatic castration-resistant prostate cancer (mCRPC) setting as "may be appropriate." This was because no available PSMA-targeted therapies would benefit from imaging using PSMA PET. With the approval of PSMA RPT, the PSMA PET AUC Working Group has split this indication into 2 distinct indications (see supplemental materials, available at http://ow.ly/ABfv30sh3uO). The first is "Posttreatment PSA rise in the mCRPC setting in a patient not value in identifying ¹⁸F-FDG-positive/PSMA-negative sites being considered for PSMA-targeted radiopharmaceutical therapy," which was again scored as "may be appropriate," because the clinical value of improved tumor localization in grossly metastatic disease is not clear in patients who are ot being considered as candidates for PSMA RPT. The second indication is "Evaluation of eligibility for patients being considered for PSMA-targeted radiopharmaceutical therapy," which was scored as "appropriate" given the availability of a PSMA-targeted therapy.

NEWSLIN

An important point is that the AUC Working Group agreed that both ¹⁸F-DCFPyL (Pylarify, ¹⁸F-piflufolastat; Lantheus [Billerica, MA]) and 68Ga-PSMA-11 (Illuccix and Locametz, 68Ga-gozetotide; Telix Pharmaceuticals Ltd. [Melbourne, Australia], and Novartis/AAA, respectively) should be considered equivalent for selection of patients for treatment with 177Lu-PSMA-617. In the prescribing information for 177Lu-PSMA-617, the FDA recommended selection of "patients for treatment using Locametz or an approved PSMA-11 imaging agent based on PSMA expression in tumors." However, given the near equivalency of 68Ga-PSMA-11 and 18F-DCFPyL, either of these radiotracers can be used for patient selection.

Another consideration for patient selection is what cutoff should make a patient eligible. Two randomized trials have evaluated 177Lu-PSMA-617 therapy: the VISION and TheraP

Hope & Jadvar. J Nucl Med **May 2022**

s an indication of how quickly the field of nuclear trials. Optimal PSMA PET criteria for patient selection are not medicine is advancing, the Appropriate Use Criteria yet well established. In the VISION trial, eligibility required uptake in disease greater than that in the liver, and no measurity in the TheraP study required an SUV ≥20 at 1 site of disease, an SUV ≥10 at measurable soft tissue sites, and no 18F-FDG-positive PSMA-negative sites of disease (3). It should be noted that, in general, the higher the uptake on PSMA PET, the better patients respond to treatment (4,5). PSMA PET is not only a prognostic biomarker but was shown to be predictive in the TheraP trial, with patients who had an SUV_{mean} ≥10 having a higher likelihood of PSA response compared to chemotherapy (cabazitaxel) (6). Although the decision in the VISION trial was binary, uptake may be used to help weigh various treatment options. The debate as to whether ¹⁸F-FDG PET/CT should also be used to screen patients prior to PSMA RPT is outside of the scope of the PSMA PET AUC, although ¹⁸F-FDG PET may provide additional

of disease (3). PSMA PET plays a significant role in the appropriate selection of patients for PSMA RPT. With the approval and availability of 2 PSMA PET agents, this imaging study should be widely available. Overall, these 2 imaging agents are considered equivalent for patient selection.

REFERENCES

1. Jadvar H, Calais J, Fanti S, et al. Appropriate use criteria for prostate-specific membrane antigen PET imaging. J Nucl Med. 2022;63:59-68.

2. Kuo PH, Benson T, Messmann R, Groaning M. Why we did what we did PSMA-PET/CT selection criteria for the VISION trial. J Nucl Med. January 2022:inumed.121.263638

Hofman MS, Goh JC, Tan TH, et al. [177LulLu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised open-label, phase 2 trial. Lancet. 2021;351:1502-1506.

4. Gafita A, Calais J, Grogan TR, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: An international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115-1125

5. Seifert R, Seitzer K, Herrmann K, et al. Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy. Theranostics. 2020;10:7812-7820.

6. Buteau JP, Martin AJ, Emmett L, et al. PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of ¹⁷⁷Lu-PSMA-617 (LuP-SMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603) [abstract]. J Clin Oncol. 2022; 40(6; suppl):10-10.

Table 2

Clinical Scenarios for PSMA PET

Scenario no.	Description	Appropriateness	Score
1	Patients with suspected prostate cancer (e.g., high/rising PSA levels, abnormal digital rectal examination results) evaluated for targeted biopsy and detection of intraprostatic tumor	Rarely appropriate	3
2	Patients with very low, low, and favorable intermediate-risk prostate cancer	Rarely appropriate	2
3	Newly diagnosed unfavorable intermediate, high-risk, or very high-risk prostate cancer	Appropriate	8
4	Newly diagnosed unfavorable intermediate, high-risk, or very high-risk prostate cancer with negative/equivocal or oligometastatic disease on conventional imaging	Appropriate	8
5	Newly diagnosed prostate cancer with widespread metastatic disease on conventional imaging	May be appropriate	4
6	PSA persistence or PSA rise from undetectable level after radical prostatectomy	Appropriate	9
7	PSA rise above nadir after definitive radiotherapy	Appropriate	9
8	PSA rise after focal therapy of the primary tumor	May be appropriate	5
9	nmCRPC (M0) on conventional imaging	Appropriate	7
10	Posttreatment PSA rise in the mCRPC setting in a patient not being considered for PSMA-targeted radioligand therapy	May be appropriate	5
11	Evaluation of eligibility for patients being considered for PSMA-targeted radioligand therapy	Appropriate	9
12	Evaluation of response to therapy	May be appropriate	5

- Scenario 1: Patients with suspected prostate cancer to evaluate for targeted biopsy and detection of intraprostatic tumor (Score 3 – Rarely Appropriate)
 - Limited evidence; PSMA expression heterogeneous and may be negative in both primary tumor and metastases (5-10%)
 - May be considered when mpMRI is inconclusive (~13% miss rate for csPC) or prior biopsy results are negative
 - PRIMARY: multicenter prospective phase II imaging trial (n=296) to provide evidence on added value of PSMA PET to mpMRI for detecting csPC (ISUP>2) and reduction in unnecessary bx – Emmett, Eur Eurol 2021
 - PSMA PET+mpMRI improved sensitivity over mpMRI alone (97% v. 83%, p<0.001) at cost of reduced specificity (40% v. 53%, p=0.011)
 - 19% with neg. PSMA PET+mpMRI could avoid bx at risk of delaying csPC detection in 3.1%

- Scenario 2: Patients with very low, low, and favorable intermediate-risk prostate cancer (Score 2 – Rarely Appropriate)
 - NCCN guidelines risk stratification
 - Imaging generally not indicated
 - Initial management offen observation or active surveillance
 - Paucity of evidence, morbidity and financial cost associated with screening for clinically insignificant prostate cancer

- Scenario 3: Newly diagnosed unfavorable intermediate-, high-, or very high-risk prostate cancer (Score 8 – Appropriate)
 - NCCN guidelines risk stratification
 - Supportive evidence for PSMA PET as more informative than conventional imaging
 - proPSMA: ⁶⁸Ga-PSMA-11, randomized trial comparing PSMA
 PET and CI for staging high-risk prostate cancer Hofman, Lancet 2020
 - PSMA > CI -- accuracy, impact
 - PSMA < CI -- equivocal findings, radiation, cost

 OSPREY: ¹⁸F-DCFPyL, Cohort A, high-risk, pelvic LN involvement: specificity 97.9%, sensitivity 40.3% - Pienta, J Urol 2021

- Scenario 4: Newly diagnosed unfavorable intermediate-, high-, or very high-risk prostate cancer with negative/equivocal or oligometastatic disease on conventional imaging (Score 8 – Appropriate)
 - NCCN guidelines risk stratification
 - Some clinicians may continue to use CI initially; will take time before adoption of PSMA PET
 - PSMA PET may identify sites of disease not detected on CI including oligometastatic disease amenable to MDT
 - Oligometastatic disease on CI may be polymetastatic disease on PSMA PET

- Scenario 5: Newly diagnosed prostate cancer with widespread metastatic disease on conventional imaging (Score 4 – May Be Appropriate)
 - Little evidence that PSMAPET adds additional value or have management impact
 - Until approval of PSMA RLT, scored as "may be appropriate"

PSMA PET AUC Biochemical Recurrence

- Scenario 6: PSA persistence or PSA rise from undetectable level after radical prostatectomy (Score 9 – Appropriate)
 - Supportive evidence with impact on clinical management
 - Calais, Lancet Oncol 2019 (¹⁸F-Fluciclovine vs. ⁶⁸Ga-PSMA-11)
 - Fendler, JAMA Oncol 2019 (68Ga-PSMA-11)
 - CONDOR: ¹⁸F-DCFPyL, phase 3, uninformative CI, 49.5% post-RP Morris, Clin Cancer Res 2021
 - **OSPREY:** ¹⁸F-DCFPyL, Cohort B Pienta, J Urol 2021
 - Trials underway whether change in management improves patient outcome
 - PSMA-SRT: randomized phase 3, PSMA- vs. CI-guided salvage RT planning for recurrent prostate cancer - Calais, Eur Urol Focus 2021
 - <u>No PSA threshold defined</u>; other risk factors; disease detection & salvage Rx below AUA definition of BCR

PSMA PET AUC Biochemical Recurrence

- Scenario 7: PSA rise above nadir after definitive radiotherapy (Score 9 – Appropriate)
 - Supportive evidence with impact on clinical management similar to Scenario 6
 - Panel consensus not to limit utility of PSMA PET to only BCR defined by ASTRO-Phoenix criteria
 - Treatment often occurs before BCR threshold
 - Other factors than PSA may play role (e.g., PSADT)

PSMA PET AUC Biochemical Recurrence

- Scenario 8: PSA rise after focal therapy of primary tumor (Score 5 – May Be Appropriate)
 - Scarce data
 - Unclear definition of BCR after focal therapy
 - Focal therapy often used in low-grade primary tumor
 - Refer to Scenario 2

- Scenario 9: nmCRPC (M0) on conventional imaging (Score 7 – Appropriate)
 - M0 on CI is often positive on PSMA PET
 - All drugs approved for M0 CRPC space are also approved for metastatic setting
 - Oligometastatic disease may be amenable to MDT with some supportive data on effectiveness
 - **STOMP:** choline, observation vs. MDT Ost, J Clin Oncol 2018
 - **POPSTAR:** ¹⁸F-NaF, 48% ADT-free surv. with MDT Siva, Eur Urol 2018
 - ORIOLE: PSMA, 95% 6-mo PFS vs. 62% with CI-guided MDT Phillips, JAMA Oncol 2020


- Scenario 10: Posttreatment PSA rise in the mCRPC setting in a patient not being considered for PSMAtargeted radioligand therapy (Score 6 – May Be Appropriate)
 - Unclear how improved staging with PSMA PET over CI improves management of patients with mCRPC
 - PSMA RLT combination therapy may still have a role in individual patients

- Scenario 11: Evaluation of eligibility for patients being considered for PSMA-targeted radioligand therapy (Score 9 – Appropriate)
 - LuPSMA: PSA50 of 57% Hofman, Lancet Oncol 2018
 - TheraP: PSMA RLT vs. cabazitaxel Hofman, Lancet 2021
 - higher PSA50, longer PFS, fewer Gr 3/4 AEs than cabazitaxel
 - VISION: PSMA RLT vs. BSC Sartor, NEJNM 2021
 - <u>rPFS</u>: 8.7 m vs. 3.4 m (HR 0.40)
 - <u>OS</u>: 15.3 vs. 11.3 m (HR 0.62)
 - FDA approval of ¹⁷⁷Lu-vipivotide tetraxetan (Pluvicto)


- Scenario 12: Evaluation of response to therapy (Score 5 – May Be Appropriate)
 - Limited data and not validated in clinical trials
 - Androgen axis targeting drugs may affect PSMA expression which may not correlate with response
 - Effect of various other current and emerging therapies on PSMA expression needs additional studies
 - May be useful in PSMA RLT response assessment

PSMA Radiopharmaceutical Therapy Role of FDG


Metastatic Castrate-Sensitive Prostate Cancer Sum of SUVmax (SUM) as Predictor of THTF (time to change from ADT to chemoRx or death) Jadvar, JNM 2019 NIH R01-CA111613



Metastatic Castrate-Resistant Prostate Cancer Sum of SUVmax (SUM) as Predictor of OS Jadvar, JNM 2013 NIH R01-CA111613



FDG PET/CT in mCRPC: Treatment Response Evaluation



USC Norris Comprehensive Cancer Center

Jadvar, JNM 2013

NIH R01-CA111613






2020; 10(7): 3254-3262. doi: 10.7150/thno.39838

Research Paper

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria

Erik M. Velez¹, Bhushan Desai¹, Lingyun Ji², David I. Quinn³, Patrick M. Colletti¹, Hossein Jadvar¹




47 mCRPC pts; FDG PET/CT at baseline & 4-m post-chemoRx Rts with progressive disease by both PERICST 1.0 and PSA response criteria had significantly worse OS (12-m OS: 31% ± 14%) compared to pts with progressive disease by either response criteria alone

Velez...Jadvar, *Theranostics* 2020 NIH R01-CA111613

JAMA Oncol 2017

Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer

Josef J. Fox, MD; Somali C. Gavane, MD; Estelle Blanc-Autran, MD; Sadek Nehmeh, PhD; Mithat Gönen, PhD; Brad Beattie, MS; Hebert A. Vargas, MD; Heiko Schöder, MD; John L. Humm, PhD; Samson W. Fine, MD; Jason S. Lewis, PhD; Stephen B. Solomon, MD; Joseph R. Osborne, MD, PhD; Darren Veach, PhD; Charles L. Sawyers, MD; Wolfgang A. Weber, MD; Howard I. Scher, MD; Michael J. Morris, MD; Steven M. Larson, MD



mCRPC Tumor Heterogeneity (PSMA-/FDG+)

- 22% concordance between ¹⁸F-DCFPyL and FDG (Fourquet, JNM 2021)
- PSMA-/FDG+ associated with significantly shorter OS (Khreish, Cancers 2021, Michalski, EJNMMI 2021)
- LuPSMA trial ineligible patients with PSMA-/FDG+ mets had poor OS of 2.5 m despite additional systemic therapy (Thang, Eur Urol Oncol 2019)
- 13% patients with new PSMA-/FDG+ mets after 2 LuPSMA cycles (Hartrampf, Cancers 2021)

Prediction of Discordant (PSMA-/FDG+) mCRPC

- 23.2% total discordance between ⁶⁸Ga-PSMA-11 & FDG (Chen, JNM 2021)
 - GS<8 & PSA<7.9 ng/mL \rightarrow No mismatch
 - GS<8 & PSA>7.9 ng/mL → 21.7% mismatch
 - GS>8 & PSA>7.9 ng/mL -> 61.5% mismatch
- Liquid biopsy
 - Neuron-specific enolase (Rosar, EJNMMI Res 2020)
 - LDH, ALP (Ferdinadus, EJNMMI 2020)

[¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study



LuPSMA Lancet Oncol 2018

Michael S Hofman^{*}, John Violet^{*}, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu

- 30 men mCRPC
- Prior Rx: 87% chemo, 83% ADT
- PSMA+ / FDG-
- RLT: 7.5 GBq/cycle x 4 cycles q6w
 - 1 (100%), 2 (93%), 3 (80%), 4 (47%)
- PSA50 -- 57% of patients
- 82% objective response
- 37% improvement in global health




Figure 3: (A) PSA response after 12 weeks* and (B) best PSA response from


[¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial


Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie K Rutherford, Andrew Weickhardt, Andrew M Scott, Sze-Ting Lee, Edmond M Kwan, Arun A Azad, Shakher Ramdave, Andrew D Redfern, William Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y Zhang, Margaret M McJannett, Martin R Stockler, John A Violet*, Scott G Williams, Andrew J Martin, Ian D Davis, for the TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group†

	[¹⁷⁷ Lu]Lu-PSMA-617 (n=98)		Cabazitaxe (n=85)	il.
	Grade 1-2	Grade 3-4	Grade 1-2	Grade 3-4
Fatigue	69 (70%)	5 (5%)	61 (72%)	3 (4%)
Pain*	60 (61%)	11 (11%)	52 (61%)	4 (5%)
Dry mouth	59 (60%)	0	18 (21%)	0
Diarrhoea	18 (18%)	1 (1%)	44 (52%)	4 (5%)
Nausea	39 (40%)	1 (1%)	29 (34%)	0
Thrombocytopenia	18 (18%)	11 (11%)	4 (5%)	0
Dry eyes	29 (30%)	0	3 (4%)	0
Anaemia	19 (19%)	8 (8%)	11 (13%)	7 (8%)
Neuropathy†	10 (10%)	0	22 (26%)	1 (1%)
Dysgeusia	12 (12%)	0	23 (27%)	0
Haematuria	3 (3%)	1 (1%)	12 (14%)	5 (6%)
Neutropenia‡	7 (7%)	4 (4%)	4 (5%)	11 (13%)
Insomnia	9 (9%)	0	12 (14%)	1 (1%)
Vomiting	12 (12%)	1 (1%)	10 (12%)	2 (2%)
Dizziness	4 (4%)	0	11 (13%)	0
Leukopenia	10 (10%)	1 (1%)	5 (6%)	1 (1%)
Any adverse event	53 (54%)	32 (33%)	34 (40%)	45 (53%)

Data are n (%). Events that occurred in at least 10% of participants are shown. ¹⁷⁷Lu=Lutetium-177. PSMA=prostate-specific membrane antigen. *Including bone, buttock, chest wall, flank, neck, extremity, tumour pain, or pelvic pain. †Motor or sensory. ‡Febrile neutropenia.

Table 2: Adverse events





-N: CBZ (85), Lu (98) -No FDG+/PSMA - (28%) -PSA50: (CBZ 44% < Lu 66%)

-Gr. 3/4 AE (no xerostomia)





TheraP Lancet 2021

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial TheraP

James P Buteau, Andrew J Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M Joshua, Roslyn J Francis, Alison Y Zhang, Andrew M Scott, Sze-Ting Lee, Arun A Azad, Margaret M McJannett, Martin R Stockler, Scott G Williams, Ian D Davis, Michael S Hofman, for the TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group* A PSA response n/N % (95% CI) OR (95% CI) FDG MTV <200 mL 56% (48-65) 79/140 ref FDG MTV ≥200 mL 23/60 38% (26-52) 0.44 (0.23-0.84) 65% (50-78) Q1: FDG MTV <23 mL 32/49 ref Q2: FDG MTV ≤23 mL to <83 mL 26/51 51% (37-65) 0.51(0.21 - 1.17)Q3: FDG MTV = 83 mL to < 250 mL 24/50 48% (34-62) 0.42 (0.17-0.97) Q4: FDG MTV ≥250 mL 20/50 (27 26 0.31 (0.13-0.73) 0.50 1.0 2:0 4.0 B Radiographic progression-free survival Median, months (95% CI) n/N HR (95% CI) 110/140 9.1 (8.2-10.5) FDG MTV <200 mL ref FDG MTV ≥200 mL 0/60 6.0(5.2 - 8.1)1.79 (1.28-2.52) Q1: FDG MTV <23 mL 37/49 10.6(9.4 - 12.3)ref 41/51 8.6 (7.8-10.6) Q2: FDG MTV ≤23 mL to <83 mL 1.21 (0.77-1.90) Q3: FDG MTV ≤83 mL to <250 mL 40/50 7.3 (5.4-10.4) 1.76 (1.12-2.75) Q4: FDG MTV ≥250 mL 42/50 6.0 (5.3-8.3) 2.27 (1.45-3.55) 4.0 0.25 0.50 2.0 1:0 C PSA progression-free survival n/N Median, months (95% CI) HR (95% CI) FDG MTV <200 mL 123/140 5.7 (5.2-6.8) ref FDG MTV ≥200 mL 49/60 3.6 (2.8-5.4) 1.44 (1.03-2.02) 6.2 (5.2-8.9) Q1: FDG MTV <23 mL 44/49 ref Q2: FDG MTV ≤23 mLto <83 mL 47/51 5.7 (3.9-8.3) 1.22 (0.80-1.85) Q3: FDG MTV ≤83 mL to <250 mL 1.17 (0.76-1.80) 40/50 5.3 (3.4-8.3) Q4: FDG MTV ≥250 mL 1.74(1.13 - 2.69)41/50 3.9 (2.7-5.4) 4.0 0.25 0.50 2:0

Figure 4: Post-hoc sensitivity analyses of clinical outcomes according to FDG-PET MTV

- WB PSMA PET SUVmean (< or \geq 10): predictive of response to Lu-PSMA
- WB FDG PET MTV (< or > 200 ml): prognostic of outcome regardless of Rx


VISION Trial: ¹⁷⁷Lu-PSMA versus best supportive care



Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, M.D., Johann de Bono, M.B., Ch.B., Ph.D., Kim N. Chi, M.D., Karim Fizazi, M.D., Ph.D., Ken Herrmann, M.D., Kambiz Rahbar, M.D., Scott T. Tagawa, M.D., Luke T. Nordquist, M.D., Nitin
Vaishampayan, M.D., Ghassan El-Haddad, M.D., Chandler H. Park, M.D., Tomasz M. Beer, M.D., Alison Armour, M.B., Ch.B., M.D., Wendy J. Pérez-Contreras, M.P.A., Michelle DeSilvio, Ph.D., Euloge
Kpamegan, Ph.D., Germo Gericke, M.D., Ph.D., Richard A. Messmann, M.D., M.H.S., Michael J. Morris, M.D., and Bernd J. Krause, M.D.<u>et al.</u>, for the VISION Investigators*

- 40% decline in risk of death
- 60% decline in radiographic progression
- 4-m OS benefit; 5.3-m rPFS benefit
- More side effects but low grade and manageable



- 9 Countries (NA and EU)
- >750 patients recruited
- 12-14 months FU min 15 month

<u>NOT ALLOWED</u> - chemo, Ra, immunoRx, investigational drugs <u>ALLOWED</u>: ADT, bone-directed Rx, palliative XRT

Endocyte/Novartis NCT03511664


Characterization of PSMA-/FDG+ mCRPC

- LuPSMA trial (Hofman, Lancet Oncol 2018)
 - PSMA+: met SUVmax >1.5 x liver SUVmean
 - No PSMA-/FDG+ → excluded 16%
- TheraP trial (Hofman, Lancet 2021)
 - PSMA+: met SUVmax > 20 & >10 at all measurable met sites
 - No PSMA-/FDG+ → excluded 28%
 - WB PSMA PET SUV mean (< or \geq 10); predictive of PSA response to Lu-PSMA
 - WB FDG PET MTV (sor > 200 m): prognostic of outcome (rPFS) irrespective of Rx
- VISION trial (Sartor, NEJM 2021)
 - PSMA+: at least 1 met uptake > liver for any size/organ
 - No PSMA-: uptake < liver in measurable lesions on dCT
 - LN SA \geq 2.5 cm, organ lesion \geq 1.0 cm, bone with ST component \geq 1.0 cm
 - No FDG PET/CT → excluded 12.6%

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial


Kuo, JNM 2022

Phillip H. Kuo¹, Taylor Benson², Richard Messmann², and Michael Groaning³




- Retrospective
 multicenter
- 301 mCRPC patients treated with PSMA RLT
- VISION-PET-E v.
 VISION-PET-SF
- 1. mCRPC patients treated with 177Lu-PSMA
- 2. Retrospective review of baseline PSMA PET
- 3. Application of VISION PET criteria
 - > ≥ 1 PSMA-positive metastasis (> liver)
 - ➤ No PSMA-negative metastasis (≤ liver)

- estimated 20-25% SFs in unselected pts
- Need demonstration of PSMA expression prior to PSMA RLT
- Refinement in PSMAPET selection criteria



Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis




Hotta, JNM 2022


EAU-EANM Consensus Statement PSMA PET/CT in LuPSMA RLT Fanti, Eur Urol Oncol 2022


Statement	Consensus?	MS*
PSMA PET demonstration of PSMA expression mandatory before LuPSMA RLT	Yes	9
PSMA PET for evaluation of response to LuPSMA RLT	Yes	7
PSMA PET should be performed at end of LuPSMA RLT	Yes	6
PSMA PET in majority of mCRPC pts to evaluate progression	Yes	3
PSMA PET should be performed after each cycle of LuPSMA RLT	Yes	<mark>1.5</mark>
FDG PET should be performed before LuPSMA RLT	Yes	<mark>4</mark>
FDG PET should be performed at end of LuPSMA RLT	Yes	<mark>2</mark>
FDG PET should be performed after each LuPSMA RLT cycle	Yes	<mark>1</mark>


- Delphi process (2 rounds)
- 9-point Likert scale (1=strongly disagree, 9=strongly agree)
- * MS=median scale score













PSMA/FDG phenotypes



Up to 30% PSMA-/FDG+ lesions #APCCC2019

The VISION Forward: Recognition and Implication of PSMA-/¹⁸F-FDG+ mCRPC Jadvar, JNM 2022

Hossein Jadvar



Pros & Cons of FDG PET/CT in PSMA RPT

- Pros
 - Assessment of tumor burden and beterogeneity
 - May select patients who benefit most from PSMA RPT
 - May identify pts for combined Rx (PSMA RPT+ Chemo / Irx / PARPi / ADT if PolyM; PSMA RPT+MDT if OligoM)
 - Interim FDG PET/CT during PSMA RPT may inform regarding subsequent RPT cycles timing and dosage

Jadvar, JNM 2022

Pros & Cons of FDG PET/CT in PSMA RPT

Cons

- Standardization for reproducible total tumor burden quantification & comparison of PSMA & FDG PET
- Need for simple combined PSMA+FDG PET reporting
- Inconvenience to patient & motivation to receive PSMA RLT regardless of FDG PET findings
- Iow PSMA/FDG+ pts may still benefit from PSMA RPT
- Payment for 2 PET scans
- Need for cost-utility analysis and impact on outcome

Jadvar, JNM 2022

Take-Home Message

- FDG PET in mCRPC
 - treatment response assessment in metastatic disease
 - prognostication
 - potential outcome-optimized PSMA RPT patient selection
 - <u>PSMA PET mandatory prior to PSMA RPT</u>
 - Pluvicto Package Insert
 - NCCN Guidelines (Version 4.2022, May 10, 2022)
 - Appropriate Use Criteria (Jadvar H et al, JNM 2022)

Optimal v. Required v. Practical (Sartor, JNM 2022)

Acknowledgement

NIH / NCI / NIBIB R01-CA111613 R21-CA142426 R21-EB017568 P30-CA014089



SCCTSI Souther Galifornia Clinical and Translational Science Institute

The Ming Hsieh Institute

for Research on Engineering-Medicine for Cancer

jadvar@med.usc.edu

USCUniversity of Southern California



